Tafasitamab for autoimmune blood cell disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA).
- You have not had your spleen removed.
- You have had at least one standard course of rituximab (Rituxan) in the past, with the last dose at least 6 months ago.
- Your disease is currently active and needs treatment (low platelet count for ITP, low hemoglobin for wAIHA).
- You have not had a previous anti-CD19 treatment (like a different antibody or CAR T-cell therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests a medicine called ATRA (a form of vitamin A) to see if it can help adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing bleeding and bruising. It is for people who have already tried standard treatments without lasting success.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new treatment using modified immune cells (CAR T-cells) to target and destroy the faulty cells that attack your blood cells in ITP or wAIHA. It aims to reset your immune system to stop the disease and improve blood counts.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.